JP2021530568A5 - - Google Patents

Info

Publication number
JP2021530568A5
JP2021530568A5 JP2021526193A JP2021526193A JP2021530568A5 JP 2021530568 A5 JP2021530568 A5 JP 2021530568A5 JP 2021526193 A JP2021526193 A JP 2021526193A JP 2021526193 A JP2021526193 A JP 2021526193A JP 2021530568 A5 JP2021530568 A5 JP 2021530568A5
Authority
JP
Japan
Prior art keywords
composition
use according
administered
tyrosine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530568A (ja
Filing date
Publication date
Priority claimed from US16/040,393 external-priority patent/US10751313B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/040569 external-priority patent/WO2020018291A1/en
Publication of JP2021530568A publication Critical patent/JP2021530568A/ja
Publication of JP2021530568A5 publication Critical patent/JP2021530568A5/ja
Pending legal-status Critical Current

Links

JP2021526193A 2018-07-19 2019-07-03 自閉症を処置するための組成物および方法 Pending JP2021530568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/040,393 2018-07-19
US16/040,393 US10751313B2 (en) 2013-10-22 2018-07-19 Compositions and methods for treating autism
PCT/US2019/040569 WO2020018291A1 (en) 2018-07-19 2019-07-03 Compositions and methods for treating autism

Publications (2)

Publication Number Publication Date
JP2021530568A JP2021530568A (ja) 2021-11-11
JP2021530568A5 true JP2021530568A5 (cg-RX-API-DMAC7.html) 2022-07-11

Family

ID=69164908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526193A Pending JP2021530568A (ja) 2018-07-19 2019-07-03 自閉症を処置するための組成物および方法

Country Status (6)

Country Link
US (1) US12150924B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823626A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530568A (cg-RX-API-DMAC7.html)
CN (1) CN112789045A (cg-RX-API-DMAC7.html)
AU (1) AU2019306092A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020018291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059323A1 (en) * 2022-09-16 2024-03-21 Halas Francis Peter Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine
US12488022B2 (en) * 2023-11-27 2025-12-02 Capital One Services, Llc Systems and methods for identifying data labels for submitting to additional data labeling routines based on embedding clusters

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
WO2001078704A2 (en) 2000-04-13 2001-10-25 Evans William T Gaba substrate and the use thereof for treating cognitive and emotional disorders
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
HK1078086A1 (en) 2003-04-09 2006-03-03 日本烟草产业株式会社 Heteroaromatic pentacyclic compound and medicinal use thereof
WO2006039691A2 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
WO2006099288A2 (en) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
ES2327421T3 (es) 2005-03-11 2009-10-29 Gpc Biotech Ag Terapia antiproliferativa combinada que comprende satraplatino o jm118 y docetaxel.
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
AU2009221120A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
WO2010022243A1 (en) 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10751313B2 (en) * 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) * 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2016247301A1 (en) * 2015-04-14 2017-10-26 Steven Hoffman Compositions and methods for treating autism

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2021527092A5 (cg-RX-API-DMAC7.html)
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JP2022153638A5 (cg-RX-API-DMAC7.html)
JPS6143112A (ja) 精神性欲機能障害治療剤
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2018507243A5 (cg-RX-API-DMAC7.html)
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
JP2019513814A5 (cg-RX-API-DMAC7.html)
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
JP2022521233A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2016505050A5 (cg-RX-API-DMAC7.html)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2024084670A5 (cg-RX-API-DMAC7.html)
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
AU2018371628B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP2024506041A5 (cg-RX-API-DMAC7.html)
RU2590978C1 (ru) Капсулированный препарат для лечения простуды и способ его получения
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
JP2022521208A5 (cg-RX-API-DMAC7.html)
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
JP2024518455A5 (cg-RX-API-DMAC7.html)